Nutriband Inc.
NASDAQ:NTRBBiotechnology
+$0.85 today
- Market cap
- $58.59M
- Beta
- 1.97
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.66
Volume 0.03M
Average 0.01M
NTRB Interest Expense
Cost of servicing the company's debt during the period.
Nutriband Inc.NASDAQ: NTRB
Interest Expense · Q1 FY2026 · quarter ended Apr 2026
Interest expense dips below year-ago levels
Q1 FY2026 interest expense of $5.01K fell 14.8% year over year, behind the +16.0% change in trailing-twelve-month interest expense. Sequentially, it fell 6.1% from the prior quarter. Over 3 fiscal years it compounded at +39.6% a year.
Context
- Interest expense amounted to 1.1% of revenue in FY2025, up 0.1 pp from a year earlier.
- Interest expense increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -14.8% toward the trailing-twelve-month pace of +16.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 22.54K USD
- Year-over-year change
- +5.3%
- 4-year CAGR
- -34.0%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2026-01-31 | 22.54K | +5.3% |
| FY2024 | 2025-01-31 | 21.41K | -71.8% |
| FY2023 | 2024-01-31 | 75.82K | +814.6% |
| FY2022 | 2023-01-31 | 8.29K | -93.0% |
| FY2021 | 2022-01-31 | 118.42K | — |
Interest Expense vs competitors
How NTRB compares with its peers on the latest reported figures
- NTRB's LTM Apr 2026 interest expense of $21.66K is the 5th highest of the 9 companies compared; the peer median is $29.5K.
- Its year-over-year change of +16.0% is the 2nd highest of 5, against a peer median of -23.2%.
- Interest expense amounts to 1.2% of revenue for NTRB, versus a peer median of 30.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $9.57M | -28.8% | -13.9% | 14.5% | |
| LTM Mar 2026 | $2.78M | -17.6% | +33.0% | 30.4% | |
| LTM Jun 2024 | $974.16K | — | -12.6% | 119.4% | |
| LTM Mar 2026 | $59K | +2850.0% | -23.4% | — | |
| LTM Apr 2026 | $21.66K | +16.0% | +39.6% | 1.2% | |
| LTM Mar 2026 | $0 | — | — | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $0 | — | — | — |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding NTRB) | $29.5K | -23.2% | -13.2% | 30.4% | |
Competitors are the stored peer set for NTRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jan 2022 | FY2022 Jan 2023 | FY2023 Jan 2024 | FY2024 Jan 2025 | FY2025 Jan 2026 |
|---|---|---|---|---|---|
| Revenue | 1.42M | 2.08M | 2.09M | 2.14M | 2.04M |
| Cost of Revenue | 917.84K | 1.33M | 1.22M | 1.44M | 1.47M |
| Gross Profit | 504.31K | 750.41K | 862.11K | 699.3K | 566.31K |
| Gross Margin | 35.5% | 36.1% | 41.3% | 32.7% | 27.8% |
| Research & Development | 411.38K | 982.23K | 1.96M | 3.12M | 1.89M |
| Selling, General & Admin | 4.02M | 3.92M | 3.77M | 4.27M | 6.99M |
| Operating Expenses | 4.43M | 4.9M | 5.73M | 7.39M | 8.88M |
| Depreciation & Amortization | 318.26K | 368.96K | 287.72K | 285.05K | 193.8K |
| EBITDA | (5.74M) | (4.11M) | (5.12M) | (10.18M) | (8.01M) |
| EBITDA Margin | -403.6% | -197.5% | -245.6% | -475.5% | -393.5% |
| Operating Income | (3.93M) | (4.15M) | (4.87M) | (6.69M) | (8.32M) |
| Operating Margin | -276.3% | -199.5% | -233.6% | -312.6% | -408.4% |
| Interest Income | 0 | 0 | 16.85K | 191.67K | 0 |
| Interest Expense | 118.42K | 8.29K | 75.82K | 21.41K | 22.54K |
| Other Income / Expenses | (2.25M) | (335.62K) | (613.39K) | (3.79M) | 88.33K |
| Income Before Tax | (6.18M) | (4.48M) | (5.49M) | (10.48M) | (8.23M) |
| Pre-Tax Margin | -434.3% | -215.6% | -263.0% | -489.9% | -404.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (8.42M) | (4.81M) | (5.49M) | (10.48M) | (8.23M) |
| Net Margin | -592.2% | -231.3% | -263.0% | -489.9% | -404.1% |
| EPS (Basic) | (1.06) | (0.57) | (0.69) | (0.99) | (2.58) |
| EPS (Diluted) | (1.06) | (0.57) | (0.69) | (0.99) | (2.58) |
| Weighted Avg Shares | 7.93M | 8.46M | 7.95M | 10.61M | 11.64M |
| Weighted Avg Shares (Diluted) | 7.93M | 8.46M | 7.95M | 10.61M | 11.64M |
Nutriband Inc.
NASDAQ:NTRB
Intrinsic Alpha fair value
Locked
Current Price
$4.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.